This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01) | MicrobiomeTrials
← Back to trials NCT07630974
A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01) Recruiting PHASE1, PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2026-07-06Est. Completion: 2031-08-17
Enrollment target: 134 participantsLocations Children's Hospital Colorado-Center for Cancer and Blood Disorders ( Site 4016), Aurora, Colorado, United States University of Iowa Hospitals ( Site 4017), Iowa City, Iowa, United States Dana Farber Cancer Center ( Site 4013), Boston, Massachusetts, United States Corewell Health ( Site 4001), Grand Rapids, Michigan, United States Rutgers Cancer Institute of New Jersey ( Site 4008), New Brunswick, New Jersey, United States Memorial Sloan Kettering Cancer Center ( Site 4010), New York, New York, United States New York Medical College ( Site 4023), Valhalla, New York, United States Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 4003), Fargo, North Dakota, United States Children's Hospital of Philadelphia (CHOP) ( Site 4021), Philadelphia, Pennsylvania, United States Sanford Children's Hospital ( Site 4015), Sioux Falls, South Dakota, United States University of Texas M.D. Anderson Cancer Center ( Site 4007), Houston, Texas, United States Intermountain - Primary Children's Hospital ( Site 4014), Salt Lake City, Utah, United States UZ Gent ( Site 4428), Ghent, Oost-Vlaanderen, Belgium Other microbiome trials you might be interested in Low Grade Astrocytoma Low Grade Glioma Metastatic Low Grade Astrocytoma Metastatic Low Grade Glioma WHO Grade 1 Glioma WHO Grade 2 Glioma
This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincr…
Birmingham, United States Est. completion Dec 31, 2030
Myelodysplastic Syndromes
Background:
Myelodysplastic syndrome (MDS) and myelodysplastic/myeloproliferative neoplasm (MDS/MPN) are blood disorder…
Rigshospitalet ( Site 4467), Copenhagen, Capital Region, Denmark
Bordeaux University Hospital - Pellegrin ( Site 4105), Bordeaux, Aquitaine, France
Centre Hospitalier Universitaire de Nantes - Hôpital Femme-Enfant-Adolescent Chu De Nantes ( Site 4104), Nantes, Loire-Atlantique, France
CENTRE LEON BERARD ( Site 4100), Lyon, Rhone, France
Rambam Health Care Campus ( Site 4674), Haifa, Israel
Sheba Medical Center ( Site 4675), Ramat Gan, Israel
Seoul National University Hospital-Pediatrics ( Site 4972), Seoul, South Korea
Asan Medical Center-Pediatrics - Pedicatric Oncology ( Site 4973), Seoul, South Korea
Hospital Sant Joan de Déu ( Site 4717), Esplugues de Llobregat, Barcelona, Spain
Hospital Niño Jesús ( Site 4715), Madrid, Madrid, Comunidad de, Spain
Hospital Universitari Vall d Hebron ( Site 4716), Barcelona, Spain
Sahlgrenska Universitetssjukhuset ( Site 4634), Gothenburg, Västra Götaland County, Sweden Bethesda, United States Est. completion Jan 1, 2030
Advanced Solid Tumor Locally Advanced Solid Tumor Metastatic Solid Tumor Platinum-resistant Ovarian Cancer Post Anti-PD-1 Melanoma 2L+ Cervical Cancer Neoadjuvant Melanoma Neoadjuvant Non-Small Cell Lung Cancer Post Anti-PD-(L)1 Non-Small Cell Lung Cancer Post Anti-PD-(L)1 Small Cell Lung Cancer Third Line or Later (3L+) HER2+ Breast Cancer Second or Third Line (2L/3L) Cervical Cancer Third-line or Later (3L+) Platinum-resistant Ovarian Cancer (PROC)
TransCon IL-2 β/γ is an investigational drug being developed for treatment of locally advanced or metastatic solid tumor…
Los Angeles, United States Est. completion Aug 2027